Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biodistribution and safety of 18F-LY3950321 in healthy subjects
NCT05775601Phase 1Completed
- Sponsor
- Avid Radiopharmaceuticals
- Start
- Feb 2023
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 18F-LY3950321 in solid tumor, sponsored by Avid Radiopharmaceuticals. Primary endpoint: 18F-LY3950321 Whole Body Effective Dose. Started Feb 2023; status: completed.
02
Drugs
18F-LY3950321
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05775601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05775601.